Literature DB >> 10210279

Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus.

A Rizzi1, G Calò, M Trevisani, M Tognetto, L Fabbri, C Mapp, R Guerrini, S Salvadori, D Regoli, P Geppetti.   

Abstract

We studied the action of nociceptin (NC) on the atropine-resistant contractions of the guinea pig isolated bronchus evoked by the electrical field stimulation (EFS), an effect that is mediated by the activation of excitatory non adrenergic-non cholinergic (eNANC) nerves and the subsequent release of tachykinins. The functional site by which NC acts in this preparation was investigated using few different NC receptor agonists and the newly discovered NC receptor antagonist, [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 ([F/G]NC(1-13)NH2). NC inhibited in a concentration dependent manner (pEC50 7.14; Em - 87 +/- 3% of control values) EFS induced contractions. NC effect was mimicked by the NC analogues, NCNH2 and NC(1-13)NH2, but not by NC(1-9)NH2. NC (1 microM) did not affect the contractile effects of exogenously applied neurokinin A (1 microM). [F/G]NC(1-13)NH2 (10 microM) completely prevented the inhibition induced by NC (1 microM), whereas naloxone (1 microM) was found inactive. Both naloxone and ([F/G]NC(1-13)NH2 were per se inactive on basal resting tone as well as on the electrically induced contractions. The present findings show that NC inhibits the atropine-resistant EFS-induced contraction in the guinea pig bronchus by inhibiting eNANC nerves, and suggest the presence of NC receptors, distinct from opioid receptors, on the nerves of the guinea pig bronchus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210279     DOI: 10.1016/s0024-3205(99)00045-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain.

Authors:  R Bertorelli; L Corradini; K Rafiq; J Tupper; G Calò; E Ongini
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.

Authors:  Bruno D'Agostino; Giuseppina Marrocco; Marilisa De Nardo; Girolamo Calò; Remo Guerrini; Luca Gallelli; Charles Advenier; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 4.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

5.  Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi.

Authors:  Christophe Faisy; Emmanuel Naline; Céline Rouget; Paul-André Risse; Emmanuel Guerot; Jean-Yves Fagon; Thierry Chinet; Nicolas Roche; Charles Advenier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-04       Impact factor: 3.000

6.  Diabetes-induced changes in the morphology and nociceptinergic innervation of the rat uterus.

Authors:  Saeed Tariq; Syed M Nurulain; Hameed Rashed; Mohamed Lotfy; Starling Bright Emerald; Surya Koturan; Kornélia Tekes; Ernest Adeghate
Journal:  J Mol Histol       Date:  2015-11-20       Impact factor: 2.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.